JD Health and Gilead Sciences Forge Strategic Partnership to Build an Integrated 'Internet+' Platform for Chronic Infectious Disease Management

On July 9, 2021, JD Health and Gilead Sciences entered into a strategic partnership in the field of digital health ecosystems. Leveraging Gilead Sciences’ expertise in antiviral therapies and JD Health’s strengths in the internet sector, both parties will deeply explore innovative practices in “Internet + Healthcare.” Together, they aim to provide more professional, safe, and convenient “one-stop” disease management solutions for patients with chronic infectious diseases, thereby accelerating efforts in the prevention and control of infectious diseases such as HIV and chronic viral hepatitis.

Signing Ceremony of the Memorandum of Strategic Cooperation

Under the memorandum of cooperation, JD Health will establish the “JD Pharmacy Liver Disease Care Center” and the “JD Pharmacy HIV Care Center,” with planned support from Gilead Sciences. Focusing on two major chronic infectious diseases—HIV and chronic viral hepatitis—the initiative aims to leverage the convenience of internet-based platforms to enhance the accessibility and ease of use of innovative medicines, thereby improving patient medication adherence and achieving better therapeutic outcomes. In addition, the platform plans to hold regular medical education lectures to raise disease awareness among patients and the general public, working together to build an integrated online-to-offline, end-to-end service model for the management and prevention and control of chronic infectious diseases.

The high degree of alignment between the two parties in terms of philosophy and development goals has laid a solid foundation for this collaboration. Guided by its strategic positioning as a “supply chain-centric, healthcare service-driven, digitally enabled health management platform covering the full user lifecycle and all scenarios,” JD Health has achieved a comprehensive and complete “Internet + Healthcare” layout. It has established an integrated online-offline health management model, capable of providing patients with convenient, efficient, professional, and safe internet-based medical services.

Regarding this collaboration, Mr. Xin Lijun, Senior Vice President of JD.com and CEO of JD Health, stated, “In recent years, JD Health has effectively integrated ‘Internet + Healthcare’ into the daily lives of a broad user base by expanding service scenarios and optimizing the service delivery chain. Through this deep partnership, we will leverage Gilead Sciences’ leading expertise in antiviral therapies. We aim not only to address patients’ treatment needs but also to actively explore the potential of using internet technologies to strengthen the prevention and control of infectious diseases, thereby contributing our share to addressing practical livelihood challenges on a global scale.”

Mr. Xin Lijun, Senior Vice President of JD.com and CEO of JD Health

As a biopharmaceutical company with profound expertise in the antiviral field, Gilead has been dedicated to driving pharmaceutical innovation over the past three decades, achieving multiple breakthroughs once deemed medically impossible. Since entering the Chinese market, the company has continuously expanded access to innovative medicines by introducing eight globally innovative drugs for the treatment of chronic hepatitis B, hepatitis C, and HIV into China. Among these, four have been included in the National Reimbursement Drug List, successfully enabling more patients to receive first-line innovative therapies at affordable prices.

In recent years, Gilead has been continuously exploring innovative models to leverage the internet and emerging technologies to further expand access to innovative medicines. During the period of normalized pandemic prevention and control, Gilead has sought to collaborate with partners to expand online channels through multiple touchpoints. By capitalizing on the advantages of the internet, the company aims to transform internet-based healthcare from merely a convenient channel for online medication purchases into a high-quality, professional, and comprehensive healthcare service ecosystem that addresses the real-world needs of users.

Mr. Jin Fangqian, Global Vice President of Gilead Sciences and General Manager of China

Mr. Jin Fangqian, Global Vice President and General Manager of China at Gilead Sciences, stated: “Since its inception, Gilead has adhered to the philosophy of being ‘patient-centric,’ not only by continuously providing breakthrough innovative medicines but also by constantly exploring and breaking new ground in innovative channels and service models to deliver tangible benefits to patients. The future of ‘Internet + Healthcare’ holds infinite possibilities. We look forward to our collaboration with JD Health, through which both parties can leverage their respective strengths. Starting from the unmet needs of patients, we aim to focus on individual patient needs and enhance their disease management experience, while also expanding our scope to address broader public health issues. Together, we will explore innovative models for the management and prevention of infectious diseases, committed to creating a better and healthier world for the public.”